Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaler training study aims to cut COPD errors

NCT ID NCT02813200

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well people with COPD can learn to use three different inhaler devices: Diskus, Breezhaler, and Respimat. Twenty-four participants were taught to use each device and then checked for mistakes. The goal is to find better ways to train patients so they get the full benefit of their medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Seretide Diskus, Ultibro Breezhaler, Spiriva Respimat
What this could lead to
If successful, this could help doctors teach patients how to use inhalers correctly, leading to better symptom control and fewer hospital visits.
What could go wrong
This is a small, completed study (24 people) that only looks at learning ability, not long-term health outcomes. Results may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

24 people

The number who actually took part.

Started

Jan 2017

Finished

Mar 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged more than 40 years, * Written informed consent, * Diagnosis of COPD according to international guidelines (GOLD 2012), * Social security or health insurance, * Women of childbearing potential with a very effective contraception according to the Haute Autorité de Santé (HAS) recommendations. Exclusion Criteria: * Previous treatment with Breezhaler®, Diskus® or Respimat® or similar device, * QT ≥ 450 ms, * Contraindications to tiotropium: hypersensitivity to tiotropium, * Contraindications to indacatérol: hypersensitivity to indacatérol, * Contraindications to salmeterol: hypersensitivity to salmeterol, * Contraindications to fluticasone: hypersensitivity to fluticasone, * Contraindications to glycopyrronium: hypersensitivity to glycopyrronium, * COPD exacerbation within 6 weeks before inclusion, * Chronic psychiatric disease, * Medical condition that may affect handling of inhaler devices, * Subject deprived of his/her liberty, * Protected adult, * Subject in exclusion period related to another protocol, * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

Contacts and locations

Locations

  • CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque

    Bordeaux, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.